B2M and neoplasm: The common expression of B2M and MHC-I on tumor cells of EMPD reported herein demonstrates that EMPD retains the cellular antigen presenting machinery that is widely regarded as beneficial for immune targeting suggesting that EMPD patients have a greater likelihood of responding to immunotherapy.